NCT01258907View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2012

Conditions
Atherosclerosis
Interventions
DRUG

MLDL1278A

Single intravenous dose

DRUG

MLDL1278A

Repeating intravenous dose

DRUG

placebo

Repeating intravenous dose

DRUG

statin, stable dose

Repeating oral dose

Trial Locations (24)

10001

New York

10029

New York

11758

North Massapequa

20010

Washington D.C.

32216

Jacksonville

32605

Gainesville

45219

Cincinnati

45227

Cincinnati

46260

Indianapolis

48073

Royal Oak

55102

Saint Paul

55455

Minneapolis

64111

Kansas City

77002

Houston

77030

Houston

80904

Colorado Springs

90502

Torrance

97239

Portland

02114

Boston

01830

Haverhill

03801

Newington

97225-3411

Portland

K1Y 4W7

Ottawa

H1T 1C8

Montreal

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

BioInvent International AB

INDUSTRY

lead

Genentech, Inc.

INDUSTRY